A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device (VELOCITY)
2018年5月2日 更新者:Abbott Medical Devices
A Feasibility Registry on Use of Actigraphy Monitoring in Degenerative Mitral Regurgitation (DMR) Subjects Receiving the MitraClip® Device
A prospective, open-label, and multi-centered feasibility registry.
研究概览
详细说明
This is a prospective, open-label, and multi-centered feasibility registry (single arm study).
Approximately 36 subjects with prohibitive risk degenerative mitral regurgitation (DMR) who receive at least 1 commercial MitraClip will be registered at up to 10 US sites.
研究类型
观察性的
注册 (实际的)
30
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- Banner University Medical Center
-
-
California
-
Los Angeles、California、美国、90048
- Cedars-Sinai Medical Center
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Hospital
-
-
Florida
-
Miami、Florida、美国、33176
- Baptist Hospital of Miami
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Foundation for Medical Education and Research
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- Carolinas Medical Center
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- The Cleveland Clinic Foundation
-
-
Virginia
-
Richmond、Virginia、美国、23226
- Bon Secours St Mary's Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Prohibitive risk degenerative mitral regurgitation (DMR) patients who receive at least 1 commercial MitraClip
描述
Inclusion Criteria:
- Subject must consent to receiving the MitraClip device
- Subject must consent, be able, and commit to wearing the Actiwatch continuously for approximately 7 months
- Subject must consent to use of their data from this registry for purposes of exploratory research and publication and presentation
Exclusion Criteria:
- Subject is not a member of vulnerable population
- Subject must not have any disabilities that preclude reliable data collection from the Actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage degenerative/disabling disease (e.g. Parkinson's disease), inability to walk or will require walking aids, etc.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Commercial MitraClip® patients
Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Observational change in daily reported activity levels (counts/min) as assessed by actigraphy, from baseline to 30 days post MitraClip implantation
大体时间:At 30 days
|
Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure
|
At 30 days
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:Pre-procedure (on day 0)
|
Pre-procedure (on day 0)
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:At 30 days
|
At 30 days
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:At 2 months
|
At 2 months
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:At 3 months
|
At 3 months
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:At 4 months
|
At 4 months
|
Levels of daily and weekly activity as assessed by actigraphy
大体时间:At 5 months
|
At 5 months
|
Patterns of daily Sleep/Wake by actigraphy
大体时间:At 6 months
|
At 6 months
|
NYHA Functional Class
大体时间:At Baseline
|
At Baseline
|
NYHA Functional Class
大体时间:At 30 days
|
At 30 days
|
Mitral Regurgitation severity
大体时间:At Baseline
|
At Baseline
|
Mitral Regurgitation severity
大体时间:Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
Mitral Regurgitation severity
大体时间:At 30 days
|
At 30 days
|
Echocardiographic assessment
大体时间:At Baseline
|
At Baseline
|
Echocardiographic assessment
大体时间:Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
Echocardiographic assessment
大体时间:At 30 days
|
At 30 days
|
Distance walked 6 minute walk test (6MWT)
大体时间:At Baseline
|
At Baseline
|
Distance walked 6 minute walk test (6MWT)
大体时间:At 30 days
|
At 30 days
|
Health-related quality of life (QoL)
大体时间:At Baseline
|
At Baseline
|
Health-related quality of life (QoL)
大体时间:At 30 days
|
At 30 days
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年11月1日
初级完成 (实际的)
2017年12月1日
研究完成 (实际的)
2017年12月1日
研究注册日期
首次提交
2016年7月20日
首先提交符合 QC 标准的
2016年8月3日
首次发布 (估计)
2016年8月8日
研究记录更新
最后更新发布 (实际的)
2018年5月7日
上次提交的符合 QC 标准的更新
2018年5月2日
最后验证
2017年5月1日
更多信息
与本研究相关的术语
其他研究编号
- 16-6001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
No intervention - registry的临床试验
-
University of Illinois at ChicagoShirley Ryan AbilityLab; Oakland University; Access Living主动,不招人
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Northwestern University主动,不招人
-
Otsuka Pharmaceutical Factory, Inc.Celerion完全的